NCT03240016 2025-01-16
ABLE
University of Michigan Rogel Cancer Center
Phase 2 Completed
Clinical Trials
3 trialsNCT02887248 2023-12-05
Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma
SCRI Development Innovations, LLC
Phase 2 Terminated
NCT00683059 2016-10-17
Single Agent Abraxane as Second Line Therapy in Bladder Cancer
Sunnybrook Health Sciences Centre
Phase 2 Completed